NCT06239402Completed
Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease
Prospective Observational Study on the Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease (PRODOAC)
Source: ClinicalTrials.gov · Last updated 20 Feb 2025
Brief summary (registry, in English)
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e. with a therapeutic indication for dual or triple antithrombotic therapy) and to analyze the outcomes of therapeutic decisions, focusing on mortality, hemorrhagic events, and ischemic events,
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 394 (actual)
- First submitted
- 25 Jan 2024
- Start date
- 28 Jul 2020
- Primary completion date
- 28 Jul 2024
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Diseases
- Atrial fibrillation
- NCT number
- NCT06239402
What you commit to
- Study type: Observational
- Participants enrolled: 394
- From 28 Jul 2020 to the primary completion date, 28 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have contraindications to direct oral anticoagulants therapy
- Patients who are indicated for direct oral anticoagulants therapy for reasons other than non valvular atrial fibrillation
Who the study is looking for
- Patient with non valvular atrial fibrillation with direct oral anticoagulants therapy
- Patient on antiplatelet therapy (acetylsalicylic acid and/or inhibitor of the P2Y12 platelet receptor)
- Patient hospitalized for percutaneous coronary intervention in the previous 7 days
- Age ≥18 years
- Estimated life expectancy ≥ 12 months
- Ability to give informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituti Clinici Scientifici Maugeri Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.